Of the total revenue, $310 million came from Europe during the last fiscal quarter, accounting for 29.3%. This represented a surprise of +5.73% as analysts had expected the region to contribute $293.21 million to the total revenue. In comparison, the region contributed $293 million, or 28.2%, and $289 million, or 26%, to total revenue in the previous and year-ago quarters, respectively. Greater China accounted for 6% of the company's total revenue during the quarter, translating to $63 million. Revenues fro ...

Core Viewpoint - The market anticipates Illumina (ILMN) to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Illumina is expected to post quarterly earnings of $1.02 per share, reflecting a year-over-year increase of +183.3% [3]. - Revenue projections stand at $1.05 billion, indicating a decline of 5.8% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.15% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Illumina is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.10% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Illumina currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Illumina exceeded the expected earnings of $0.96 per share by reporting $0.97, achieving a surprise of +1.04% [13]. - Over the past four quarters, Illumina has surpassed consensus EPS estimates three times [14]. Industry Context - Another company in the biomedical and genetics sector, Wave Life Sciences (WVE), is expected to report a loss of $0.28 per share, reflecting a year-over-year change of -12% [18]. - Wave Life Sciences anticipates revenues of $12.64 million, down 35.8% from the previous year, with an Earnings ESP of +4.85% despite a Zacks Rank of 4 (Sell) [19][20].

Core Insights - Illumina reported quarterly earnings of $0.97 per share, exceeding the Zacks Consensus Estimate of $0.96 per share, and significantly up from $0.09 per share a year ago, indicating a strong performance [1] - The company generated revenues of $1.04 billion for the quarter, surpassing the Zacks Consensus Estimate by 0.25%, although this represents a decline from $1.08 billion in the same quarter last year [2] - Illumina has outperformed consensus EPS estimates three times over the last four quarters and has topped revenue estimates four times in the same period [2] Earnings and Future Outlook - The sustainability of Illumina's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.07 on revenues of $1.06 billion, while for the current fiscal year, the estimate is $4.43 on revenues of $4.31 billion [7] - The estimate revisions trend for Illumina is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Illumina belongs, is currently in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]